New findings presented at ASH indicated that GLP-1 agonists led to a significant reduction in the risk for dangerous blood ...

Propensity-score matched analysis showed that VTE rates at 1 year were 20% lower for patients starting on a GLP-1 drug rather ...

Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with ...

People with diabetes who took medications like Ozempic or Wegovy had a lower risk of serious blood clots compared to people ...

The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1 ... in studies up to 52 weeks. Also in combination with metformin and ...

Patients who received GLP-1 RAs were compared to those who received dipeptidyl peptidase-4 (DPP-4) inhibitors; after propensity score matching, the final analysis included two cohorts of 168,428 ...

People's hearts benefited, too: Use of a GLP-1 cut a person's odds for a combination outcome of heart-related death, non-fatal heart attacks and non-fatal strokes by 14%, compared to folks taking ...

Definition: The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1 ...

Definition: The Anti-Diabetes Drugs market covers drugs to treat the metabolism disorder diabetes mellitus. It includes insulin and non-insulinotropic drugs such as glucagen-like peptide-1 (GLP-1 ...